高危局限前列腺癌全身治疗联合局部治疗的系统综述
主要结论为:ADT联合EBRT较单用EBRT改善无复发生存和总生存;多西他赛联合EBRT-ADT改善无复发生存但总生存数据未成熟;前列腺切除术后辅助ADT或多西他赛的角色尚不明确。
要点
- ADT联合EBRT较单用EBRT改善高危局限前列腺癌的无复发生存和总生存。
- 多西他赛联合EBRT-ADT改善无复发生存,但总生存数据未成熟。
- 前列腺切除术后辅助ADT或多西他赛的作用尚不明确,尤其pN0患者。
核心结论
- 长期辅助ADT联合EBRT有明确生存获益,但前列腺切除术后ADT的作用仍不明确,尤其pN0患者。
- 多西他赛联合EBRT-ADT改善无复发生存,但总生存结果未成熟。
- 新型雄激素受体通路抑制剂正在新辅助和辅助治疗中试验。
研究设计与样本
- 系统综述,检索PubMED、Embase、Cochrane Library、ESMO/ASCO年会及clinicalTrial.gov,时间2010年1月至2018年2月,遵循PRISMA声明。
主要发现
- 多项随机试验显示ADT联合EBRT在无复发生存和总生存上优于单用EBRT。
- 新辅助ADT与单纯前列腺切除术相比未显示显著改善。
- GETUG 12、RTOG 0521及STAMPEDE非转移亚组显示多西他赛联合EBRT+ADT改善无复发生存,但无转移生存数据未成熟。
- SPCG-12和VACSP#553试验显示前列腺切除术后辅助多西他赛未改善无复发生存。
- 新型雄激素通路抑制剂仅在早期试验中与主要治疗联合测试。
关键数值与推荐
- ADT联合EBRT较单用EBRT改善无复发生存和总生存(基于多项随机试验)。
- 新辅助ADT对比单纯前列腺切除术未显示显著改善。
- 多西他赛联合EBRT+ADT改善无复发生存(GETUG 12、RTOG 0521、STAMPEDE非转移亚组)。
- 前列腺切除术后辅助多西他赛未改善无复发生存(SPCG-12、VACSP#553)。
临床怎么用
- 高危局限前列腺癌推荐多学科综合治疗,全身治疗联合局部治疗。
- ADT联合EBRT可作为高危患者的标准选择之一。
- 前列腺切除术后辅助ADT或多西他赛需个体化决策,尤其pN0患者缺乏3期试验数据。
- 多西他赛联合EBRT-ADT可考虑用于改善无复发生存,但需权衡未成熟的总生存数据。
局限性
- 前列腺切除术后辅助ADT缺乏pN0患者的3期试验数据。
- 多西他赛联合EBRT-ADT的总生存数据尚未成熟。
- 新型雄激素通路抑制剂仅处于早期试验阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Systemic therapies, combined with local treatment for high-risk prostate cancer, are recommended by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field. OBJECTIVE: To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer. EVIDENCE ACQUISITION: We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial.gov between January 2010 and February 2018 following the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. EVIDENCE SYNTHESIS: Seventy-seven prospective trials were identified. According to multiple randomized trials, combining androgen deprivation therapy (ADT) with external-beam radiotherapy (EBRT) outperforms EBRT alone for both relapse-free and overall survival. Neoadjuvant ADT did not show significant improvement compared with prostatectomy alone. The role of adjuvant ADT after prostatectomy in patients with high-risk disease is still debated, with lack of data from phase 3 trials in pN0 patients. Novel androgen pathway inhibitors have been tested only in early-phase trials in addition to primary treatment. GETUG 12, RTOG 0521, and nonmetastatic subgroup of the STAMPEDE trial showed improved relapse-free survival for docetaxel in patients treated with EBRT plus ADT, although mature metastasis-free survival data are still pending. Both the SPCG-12 and the VACSP#553 trial showed no improvement in relapse-free survival for adjuvant docetaxel after prostatectomy. CONCLUSIONS: In contrast to the clearly demonstrated survival benefits of long-term adjuvant ADT when used with EBRT, its role after prostatectomy remains unclear especially in pN0 patients. Adding docetaxel to EBRT-ADT improves relapse-free survival, with immature results on overall survival. Novel androgen receptor pathway inhibitors are currently being tested in the neoadjuvant and adjuvant setting. PATIENT SUMMARY: Treatment of high-risk prostate cancer is based on a multimodality approach that includes systemic treatments. The best treatment or therapy combination remains to be defined.
引用
- Tosco L, Briganti A, D'amico AV, et al. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2018. PMID: 30286948. doi:10.1016/j.eururo.2018.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。